A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...

“We are proud to deliver on our promise for patients with this significant step forward, providing a treatment option for pediatric and adult patients living with NTRK gene fusion-positive cancers.

We recently published a list of 11 Best Breakout Stocks to Buy According to Analysts. In this article, we are going to take a ...

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that its new generation pan-TRK inhibitor zurletrectinib ...

VITRAKVI ® is now fully approved for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance ...

Vitrakvi received full FDA approval for treating NTRK gene fusion-positive solid tumors in adults and children, following its initial accelerated approval in 2018. The drug functions as a tyrosine ...

The indication is specifically for those patients who have solid tumors with a neurotrophic receptor tyrosine kinase (NTRK) gene fusion that are without a known acquired resistance mutation, are ...

Bayer’s Vitrakvi (larotrectinib) has been granted traditional approval by the US Food and Drug Administration (FDA) to treat neurotrophic receptor tyrosine kinase (NTRK) gene fusion-positive solid ...

In some rare tumors, such as salivary gland carcinoma, secretory breast cancer, and infantile fibrosarcoma, the incidence of NTRK gene fusion exceeds 90%2. It is estimated that there are about ...

VITRAKVI ® is now fully approved for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation ...